On the eve of the Chinese New Year of the Bingwu Horse, we welcomed the first peptide order (Tesamorelin, Ipamorelin,BPC 157,TB500 and so on)from a new Australian client, who completed payment before the festival and expressed a clear intention for long-term cooperation. This transaction is more than a business deal; it represents a trust entrusted across the New Year. We ensured smooth pre-holiday payment with professional and efficient processes, and we are committed to prioritizing production and shipment immediately after the holiday. Through timely and reliable service, we aim to lay a solid foundation for a lasting partnership with our Australian partner.
Chemical Nature and Mechanism of Action of Tesamorelin
Tesamorelin is a synthetic peptide composed of 44 amino acids. Its molecular formula is C221H366N72O67S. By mimicking the structure of the endogenous growth hormone-releasing factor (GRF) in the human body, a 3-hexenoyl group is added at the N-terminal tyrosine residue to enhance stability. This structural modification enables it to resist degradation by dipeptidyl peptidase-IV (DPP-IV), thereby extending its half-life to 38 minutes, which is significantly superior to the natural GRF.
The core mechanism of its action lies in activating the GRF receptors in the anterior pituitary gland, promoting the pulsatile release of growth hormone (GH). GH binds to the receptors on the surfaces of chondrocytes, osteoblasts, cardiomyocytes, hepatocytes and adipocytes, triggering a series of metabolic reactions: in adipose tissue, GH activates hormone-sensitive lipase, accelerating fat breakdown; in the liver, GH induces the synthesis of insulin-like growth factor-1 (IGF-1), further regulating glucose and lipid metabolism. This dual effect makes Tesamorelin a key molecule for regulating body fat distribution.
Clinical Applications: From HIV-related Fat Metabolism Disorders to Metabolic Syndrome Management
Breakthroughs in the Treatment of HIV-Related Fat Metabolism Disorders
After HIV-infected individuals receive highly active antiretroviral therapy (HAART), they often experience fat metabolism disorders, characterized by accumulation of visceral fat, atrophy of subcutaneous fat, and abnormal blood lipids. Tesamorelin was approved by the FDA in 2010 and became the first drug for this indication. Clinical studies have shown that daily subcutaneous injection of 2mg of Tesamorelin can reduce the area of visceral fat in HIV-infected individuals by 18%-20%, while improving triglyceride levels and insulin sensitivity, and having no significant effect on subcutaneous fat.
In 2025, the FDA-approved new formulation EGRIFTA WR further optimized the treatment plan: The new formulation adopts a concentrated formula, requiring only one preparation per week, and the single dose is reduced to 1.28mg. While maintaining bioequivalence, the patient's treatment compliance has significantly improved. This improvement is particularly applicable to patients with chronic diseases that require long-term management.
Potential Therapies for Non-alcoholic Fatty Liver Disease (NAFLD)
NAFLD is the most common chronic liver disease worldwide, and its progression is closely related to the accumulation of visceral fat. A study conducted by Massachusetts General Hospital in 2024 revealed that Tesamorelin can increase the expression of genes related to mitochondrial oxidative phosphorylation, reduce liver fat deposition, and inhibit fibrosis. Gene set enrichment analysis showed that the expression of genes related to inflammation and cell proliferation was downregulated in the treatment group, while the expression of genes related to good cancer prognosis was upregulated. This finding provides new ideas for the treatment of NAFLD, and relevant clinical trials are currently underway.
Intervention Exploration for Metabolic Syndrome
Metabolic syndrome is characterized by central obesity, insulin resistance, hypertension and abnormal lipid metabolism, and is a significant risk factor for cardiovascular diseases. Tesamorelin, by regulating the GH/IGF-1 axis, may improve the body fat distribution and glucose-lipid metabolism in patients with metabolic syndrome. Preliminary studies have shown that it can reduce waist circumference and improve insulin sensitivity, but the long-term efficacy and safety still need to be verified by large-scale clinical trials.
Safety and Medication Management
Common Adverse Reactions and Monitoring
During the treatment with Tesamorelin, the following adverse reactions need to be closely monitored:
Injection site reactions
The incidence of redness, itching, pain, etc. is approximately 30%. It is recommended to alternate injection sites to reduce the risk.
Fluid retention
Manifested as peripheral edema, joint pain, and carpal tunnel syndrome, related to sodium and water retention induced by GH, which is reversible after discontinuation of the medication.
Blood sugar fluctuations
GH may reduce insulin sensitivity. Diabetic patients need to regularly monitor their blood sugar levels and adjust their hypoglycemic regimens as necessary.
Increased IGF-1 levels
During treatment, IGF-1 levels may exceed the upper limit of the age-corrected reference range by twice or more. They should be tested every 3-6 months. Those that continue to rise should discontinue the medication.
Contraindications and Medication for Special Populations
Contraindications:Active malignant tumors, hypopituitarism, pregnant women, and those allergic to the drug components are prohibited from using.
Drug use in the elderly:Data for patients over 65 years old is limited. The status of the GH/IGF-1 axis and potential risks need to be evaluated.
Liver and kidney dysfunction:No relevant studies have been conducted. It is recommended to use with caution and closely monitor.
Drug interactions
Tesamorelin indirectly affects drug metabolism by regulating GH secretion：
CYP450 enzyme substrates: GH may induce the activity of enzymes such as CYP3A4. When used in combination with warfarin, oral contraceptives, etc., blood drug concentrations need to be monitored.
Glucocorticoids: GH inhibits the activity of 11β-hydroxysteroid dehydrogenase-1. Patients with adrenal cortical insufficiency need to increase the dosage of glucocorticoid replacement.
Future Outlook: Paradigm Shift from Treatment to Prevention
Clinical research on expanding indications
Currently, Tesamorelin demonstrates potential in the following areas:
Age-related metabolic decline
Animal experiments have shown that it can improve the muscle mass and insulin sensitivity of aged mice, and human studies are underway.
Hereditary fat metabolism disorders
The phase II trial for familial partial lipodystrophy (FPLD) showed that Tesamorelin can reduce visceral fat and improve metabolic parameters.
Cancer-related cachexia
Early studies suggest that it may improve the nutritional status and quality of life of cancer patients by regulating the GH/IGF-1 axis.
Development of new delivery systems
To enhance patient compliance, researchers are exploring the following delivery methods:
Microneedle patches: Achieve painless drug delivery through soluble microneedles, suitable for long-term self-injection.
Long-acting sustained-release formulations: Develop sustained-release microspheres that are administered once a week or once a month to reduce the injection frequency.
Oral peptide drugs: Utilize nanotechnology or penetration enhancers to improve oral bioavailability. Currently, this is still in the preclinical stage.
Optimization of individualized treatment strategies
Based on genomic and metabolomic research, in the future, the following precision medicine may be possible:
Biological markers for guiding medication: By detecting the genetic polymorphism of GRF receptor or the level of IGF-1, the best responders can be selected.
Dose adjustment algorithm: Based on weight, age and metabolic parameters, an individualized medication plan is formulated.
Exploration of combined therapy: Combined with GLP-1 receptor agonists, SGLT2 inhibitors and other drugs to exert a synergistic lipid-lowering effect.
Conclusion
Tesamorelin, as the first synthetic peptide drug targeting fat metabolism disorders, has expanded its clinical value from the management of HIV-related complications to a broader range of metabolic diseases. With a deeper understanding of the regulatory mechanism of the GH/IGF-1 axis and breakthroughs in new delivery technologies, Tesamorelin is expected to become an important treatment option for metabolic syndrome, aging-related decline, and hereditary fat disorders. In the future, through multi-center clinical trials to verify its long-term efficacy and safety, and in combination with individualized medical strategies, this field will be further developed, bringing new hope to hundreds of millions of patients with metabolic diseases worldwide.
